#FSGS
Focal segmental glomerulosclerosis (FSGS) is a nonspecific pattern of glomerular scarring in which a subset of the glomeruli show partial involvement of the glomerular tuft. It should not be confused for a specific disease.
November 17, 2026 at 5:30 PM
The clinical application of new sequencing technologies now makes it possible to interrogate the more than 30 genes described in association with FSGS in a single test. 

#TeachingPoints #kidneypath #renal #pathology
November 17, 2026 at 5:30 PM
Clinicopathologic correlation can be useful to identify patients with primary FSGS. Specifically, primary FSGS is more likely if >80% foot process effacement is present by electron microscopy and the clinical evaluation reveals nephrotic syndrome
November 17, 2026 at 5:30 PM
Focal Segmental Glomerulosclerosis Fsgs Market Research: In-Depth Study 2035 | WiseGuyReports www.wiseguyreports.com/reports/foca...
www.wiseguyreports.com
November 18, 2026 at 12:04 PM
Published simultaneously with ISGD Clinical Trials Summit 2026, a #ASNJASN study found that finerenone preserved kidney function and produced clinically meaningful reductions in proteinuria in participants with FSGS in FIND-CKD. kidney.pub/JASN1333
November 15, 2026 at 7:00 PM
Full nephrotic syndrome is frequently not present in adults with FSGS due to a genetic etiology. If suspected, testing for possible disease-causing genetic variants of disease can be performed.
November 17, 2026 at 5:30 PM
🚨 Late Breaking #1
🌟 Hiddo Heerspink on finerenone in FSGS (FIND-CKD): see albuminuria and proteinuria 🔎
👉 https://journals.lww.com/jasn/pdf/10.1681/asn.0000001333~finerenone-in-patients-with-focal-segmental
tobias-b-huber.bsky.social
#ISGDCTS2026 #ISGD #GlomerularDisease #ClinicalTrial
November 15, 2026 at 5:26 PM
Recurrence of COL4A4-Associated FSGS After Transplantation: A Case Report - Kidney International Case Reports www.kicasereports.org/article/S311...

#KICR highlights
Recurrence of COL4A4-Associated FSGS After Transplantation: A Case Report
Genetic focal segmental glomerulosclerosis (FSGS) is traditionally thought not to recur following kidney transplantation (KT). Whereas recent evidence shows recurrences in NPHS2 and CRB2 mutations, we...
www.kicasereports.org
November 7, 2026 at 9:39 PM
There seems a strong possibility that this is classic 'circulating factor' FSGS with coincidental discovery of a heterozygous COL4 mutation (present in 1+% of the population, only a small minority develop severe renal disease).
November 9, 2026 at 2:03 PM
🩺 Join the UKKA SpR webinar on Nephrotic Conditions on Tuesday 24 November, 19:00–20:00.

Lisa Wilcocks will lead a practical, case-based session on membranous nephropathy, FSGS and minimal change disease.

For current UKKA members only.

Register: https://ow.ly/PETi5102ZfH

#Nephrology
November 8, 2026 at 3:00 PM
Focal Segmental Glomerulosclerosis Treatment Market Growth Driven by Advances in Kidney Care by 2034

The global focal segmental glomerulosclerosis (FSGS) treatment market was valued at US$ 2.39 billion in 2025 and is expected to reach US$ 3.98 billion by 2034, registering a CAGR of 5.80% during…
Focal Segmental Glomerulosclerosis Treatment Market Growth Driven by Advances in Kidney Care by 2034
The global focal segmental glomerulosclerosis (FSGS) treatment market was valued at US$ 2.39 billion in 2025 and is expected to reach US$ 3.98 billion by 2034, registering a CAGR of 5.80% during 2026–2034. Focal segmental glomerulosclerosis is a kidney disorder characterized by scarring in some glomeruli, the filtering units of the kidneys. Treatment focuses on managing proteinuria, controlling disease progression, addressing underlying causes, and preserving kidney function.
www.news24.ph
November 6, 2026 at 4:42 AM
☕ Morgen findet erneut das Mittagsforum an der #FSGS statt. Diesmal wird Dr. Sebastian Schulze über sein Forschungsprojekt "Gedicht Archiv" berichten.

🔗 Zum Programm: bit.ly/4fD0BEZ

#Mittagsforum #Wintersemester202627
November 2, 2026 at 8:00 AM
📖 Case Report | Featured in AJT’s October issue: "Live donation of a deceased donor’s kidney," by Jolie Shen and Jeffrey L. Veale
buff.ly/YtqPNCc
#KidneyTransplant #OrganDonation #Transplantation #LivingDonation
October 30, 2026 at 7:31 PM
New GN in 10 🚨
Primary/secondary FSGS? Picking the right lane changes everything for your patient—from avoiding unnecessary immunosuppression to optimizing hemodynamics
Faculty hosts @kdjhaveri.bsky.social and Dr. Koyal Jain break down the clinical essentials on this GN in 10 "Board Review Bonus"🧵👇
October 29, 2026 at 2:03 PM
In this bite-sized clinical review: • Telltale signs that distinguish secondary FSGS from primary disease • Biopsy clues that reveal hyperfiltration stress vs. viral or drug triggers • How to build an effective kidney-protective regimen focused on reducing glomerular workload
October 29, 2026 at 2:03 PM
Update: sorry I’ve not been active FSGS has been affecting me a lot
October 25, 2026 at 6:16 PM
RRID:AB_2534091 from @thermofishersci.bsky.social was used by authors in their iScience paper. RRIDs improve reproducibility in scientific research. #RRID #ReproducibleResearch #BetterScience
SH3YL1-TLR5 complex-mediated vicious cycle contributes to FSGS pathogenesis
Read the full paper: SH3YL1-TLR5 complex-mediated vicious cycle contributes to FSGS pathogenesis
doi.org
October 25, 2026 at 7:00 AM
Four Educational Symposia start in 30 minutes at #KidneyWk 2026. Sessions cover FSGS, B-cell therapy, potassium homeostasis, and complement in IgAN, with continuing education credit available.

Check the Kidney Week mobile app for symposium details.
📍 Hyatt Regency Denver | 12:45–1:45 p.m. MDT
October 22, 2026 at 6:15 PM
☕ Morgen ist der erste Termin des Mittagsforums des Wintersemesters 2026/27!

Louisa Künstler wird über ihre Tätigkeit als Lehrerin berichten. Wir freuen uns!

🔗 Programm: bit.ly/4fD0BEZ

#mittagsforum #fsgs
October 19, 2026 at 6:54 AM
📅 CATALYST REMINDER | #$TVTX
October 22–24, 2026 — Clinical Data Presentations
Sparsentan analyses from SPARTAN, DUPLEX and PROTECT at ASN Kidney Week. Presentation times vary.
🔗 Full details: www.merlintrader.com/travere-ther...
#TVTX #Biotech #KidneyWeek
Travere ($TVTX): FILSPARI And An FSGS Patent Allowance
Travere Therapeutics (TVTX) stock hub: FILSPARI sales up 96%, the allowed FSGS patent pointing to 2037 coverage, liquidity and the December CEO handover.
www.merlintrader.com
October 17, 2026 at 5:32 PM